SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia
Publication/Presentation Date
11-2020
Volume
136
Issue
Supp 1
First Page
4
Last Page
5
Published In/Presented At
Stephane De Botton, Thomas Cluzeau, Carlos Enrique Vigil, Rachel J. Cook, Philippe Rousselot, David A Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Michael R. Savona, Don Park, Michael J. Kelly, Angela Volkert, Li Zhou, Qing Kang-Fortner, David A. Roth, Eytan M. Stein; SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. Blood 2020; 136 (Supplement 1): 4–5. doi: https://doi.org/10.1182/blood-2020-134600
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS